Literature DB >> 24487793

Biomarkers in renal cancer.

Holger Moch1, John Srigley, Brett Delahunt, Rodolfo Montironi, Lars Egevad, Puay Hoon Tan.   

Abstract

Treatment options for primary and metastatic renal cancer are increasing. Accurate data from the pathological examination of renal cancer specimens aid clinicians in stratifying patients for surveillance and adjuvant therapies. This review focuses on biomarkers in diagnosis, prognosis and prediction of the biologic behavior of renal tumors which should be recorded in pathology reports and which are under investigation. Special emphasis is given to the use of immunohistochemical markers in differential diagnosis of various renal tumor subtypes. The relevance of cytogenetic and molecular findings is also discussed. The review includes the 2012 International Society for Urological Pathology Consensus conference recommendations.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24487793     DOI： 10.1007/s00428-014-1546-1

Source DB:  PubMed          Journal:  Virchows Arch        ISSN： 0945-6317            Impact factor:   4.064


  59 in total

1.  A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation.

Authors:  P Argani; A Hawkins; C A Griffin; J D Goldstein; M Haas; J B Beckwith; C B Mankinen; E J Perlman
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

2.  The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia.

Authors:  John R Srigley; Brett Delahunt; John N Eble; Lars Egevad; Jonathan I Epstein; David Grignon; Ondrej Hes; Holger Moch; Rodolfo Montironi; Satish K Tickoo; Ming Zhou; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

3.  Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer.

Authors:  Corinne Dahinden; Barbara Ingold; Peter Wild; Gunther Boysen; Van-Duc Luu; Matteo Montani; Glen Kristiansen; Tullio Sulser; Peter Bühlmann; Holger Moch; Peter Schraml
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

4.  Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.

Authors:  Toni K Choueiri; Meredith M Regan; Jonathan E Rosenberg; William K Oh; Jessica Clement; Angela M Amato; David McDermott; Daniel C Cho; Michael B Atkins; Sabina Signoretti
Journal:  BJU Int       Date:  2010-03-02       Impact factor: 5.588

5.  Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.

Authors:  Carol Peña; Chetan Lathia; Minghua Shan; Bernard Escudier; Ronald M Bukowski
Journal:  Clin Cancer Res       Date:  2010-07-22       Impact factor: 12.531

6.  Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma.

Authors:  Semra Olgac; Brian Hutchinson; Satish K Tickoo; Victor E Reuter
Journal:  Mod Pathol       Date:  2006-02       Impact factor: 7.842

7.  Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR.

Authors:  Pedram Argani; Marick Laé; Brian Hutchinson; Victor E Reuter; Margaret H Collins; John Perentesis; John E Tomaszewski; John S J Brooks; Geza Acs; Julia A Bridge; Sara O Vargas; Ian J Davis; David E Fisher; Marc Ladanyi
Journal:  Am J Surg Pathol       Date:  2005-02       Impact factor: 6.394

8.  Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.

Authors:  Whitney M Green; Raluca Yonescu; Laura Morsberger; Kerry Morris; George J Netto; Jonathan I Epstein; Peter B Illei; Mohamad Allaf; Marc Ladanyi; Constance A Griffin; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2013-08       Impact factor: 6.394

9.  MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients.

Authors:  Angelo Gámez-Pozo; Luis M Antón-Aparicio; Cristina Bayona; Pablo Borrega; María I Gallegos Sancho; Rocío García-Domínguez; Teresa de Portugal; Manuel Ramos-Vázquez; Ramón Pérez-Carrión; María V Bolós; Rosario Madero; Iker Sánchez-Navarro; Juan A Fresno Vara; Enrique Espinosa Arranz
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

Review 10.  Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability.

Authors:  Christian Eichelberg; Kerstin Junker; Börje Ljungberg; Holger Moch
Journal:  Eur Urol       Date:  2009-01-13       Impact factor: 20.096
View more
  13 in total

1.  [The WHO/ISUP grading system for renal carcinoma].

Authors:  H Moch
Journal:  Pathologe       Date:  2016-07       Impact factor: 1.011

2.  Differential expression of microRNA501-5p affects the aggressiveness of clear cell renal carcinoma.

Authors:  Alessandra Mangolini; Anna Bonon; Stefano Volinia; Giovanni Lanza; Roberto Gambari; Paolo Pinton; Gian Rosario Russo; Laura Del Senno; Lucio Dell'Atti; Gianluca Aguiari
Journal:  FEBS Open Bio       Date:  2014-11-04       Impact factor: 2.693

3.  Construction and analysis of circular RNA molecular regulatory networks in clear cell renal cell carcinoma.

Authors:  Chuanyu Ma; Jie Qin; Junpeng Zhang; Xingli Wang; Dongjun Wu; Xiunan Li
Journal:  Mol Med Rep       Date:  2019-11-11       Impact factor: 2.952

4.  DNA Methylation-Based Panel Predicts Survival of Patients With Clear Cell Renal Cell Carcinoma and Its Correlations With Genomic Metrics and Tumor Immune Cell Infiltration.

Authors:  Xiao-Ping Liu; Lingao Ju; Chen Chen; Tongzu Liu; Sheng Li; Xinghuan Wang
Journal:  Front Cell Dev Biol       Date:  2020-10-15

5.  Circular RNA circSDHC serves as a sponge for miR-127-3p to promote the proliferation and metastasis of renal cell carcinoma via the CDKN3/E2F1 axis.

Authors:  Junjie Cen; Yanping Liang; Yong Huang; Yihui Pan; Guannan Shu; Zhousan Zheng; Xiaozhong Liao; Mi Zhou; Danlei Chen; Yong Fang; Wei Chen; Junhang Luo; Jiaxing Zhang
Journal:  Mol Cancer       Date:  2021-01-20       Impact factor: 27.401

Review 6.  The role of epigenetics in kidney malignancies.

Authors:  Alfredo Harb-De la Rosa; Matthew Acker; Sanjaya Swain; Murugesan Manoharan
Journal:  Cent European J Urol       Date:  2015-04-20

7.  A Five-Gene Signature Predicts Prognosis in Patients with Kidney Renal Clear Cell Carcinoma.

Authors:  Yueping Zhan; Wenna Guo; Ying Zhang; Qiang Wang; Xin-jian Xu; Liucun Zhu
Journal:  Comput Math Methods Med       Date:  2015-10-11       Impact factor: 2.238

8.  Proteotranscriptomic Analysis Reveals Stage Specific Changes in the Molecular Landscape of Clear-Cell Renal Cell Carcinoma.

Authors:  Benjamin A Neely; Christopher E Wilkins; Laura A Marlow; Dariya Malyarenko; Yunee Kim; Alexandr Ignatchenko; Heather Sasinowska; Maciek Sasinowski; Julius O Nyalwidhe; Thomas Kislinger; John A Copland; Richard R Drake
Journal:  PLoS One       Date:  2016-04-29       Impact factor: 3.240

9.  Prognostic Value of Plasma and Urine Glycosaminoglycan Scores in Clear Cell Renal Cell Carcinoma.

Authors:  Francesco Gatto; Marco Maruzzo; Cristina Magro; Umberto Basso; Jens Nielsen
Journal:  Front Oncol       Date:  2016-11-24       Impact factor: 6.244

10.  miR-19b serves as a prognostic biomarker of breast cancer and promotes tumor progression through PI3K/AKT signaling pathway.

Authors:  Chuansheng Li; Jingwei Zhang; Zhongliang Ma; Fan Zhang; Wenlong Yu
Journal:  Onco Targets Ther       Date:  2018-07-16       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.